Dyadic International (DYAI)
NASDAQ:DYAI
Want to see DYAI full AI Analyst Report?
DYAI Stock Chart & Stats
$0.93
-$0.19(-9.79%)
At close: 4:00 PM EST
$0.93
-$0.19(-9.79%)
Day’s Range― - ―
52-Week Range$0.65 - $1.35
Previous CloseN/A
Volume131.09K
Average Volume (3M)396.96K
Market Cap
$24.86M
Enterprise Value$29.34M
Total Cash (Recent Filing)$6.52M
Total Debt (Recent Filing)$5.05M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 12, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding36,438,700
10 Day Avg. Volume144,364
30 Day Avg. Volume396,964
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)24.88
Price to Sales (P/S)24.89
P/FCF Ratio-5.38
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue9.86
Enterprise Value/Gross Profit31.55
Enterprise Value/Ebitda-4.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$6.82M
Bulls Say, Bears Say
Bulls Say
Strong YoY Revenue Growth And Product LaunchesSustained 182% YoY revenue growth and multiple commercial product shipments indicate early market acceptance of the C1 platform. Over 2–6 months this supports increasing recurring product and OEM revenues, validating commercial demand and improving the company's ability to convert partner engagements into scalable sales.
Platform De‑risking Via Grants And Clinical DataLarge grant-funded programs and completed Phase I plus preclinical antibody comparability data materially de‑risk the C1 technology. This scientific validation strengthens licensing prospects, encourages partner R&D investments, and raises the long‑term probability of royalty streams and biopharma adoption.
Diverse Commercialization Channels And PartnershipsMultiple go‑to‑market pathways (OEM distribution, licensing, profit‑share, direct sales) plus established partners let Dyadic scale reach without heavy capex. This business model diversification reduces single‑product concentration risk and supports steadier, partner-driven revenue growth over the medium term.
Bears Say
Deteriorated Balance Sheet And Rising DebtNegative equity and rising debt materially weaken financial flexibility and increase leverage risk. Over the coming months this constrains options for investing in scale, raises the odds of future financing at dilutive terms, and limits the firm's ability to withstand execution delays or larger-than-expected cash needs.
Persistent Negative Operating Cash Flow And BurnOngoing negative operating cash flow and a finite runway increase financing dependence. Even with improved burn versus prior years, the company needs either accelerating product revenues or external capital within ~12 months, creating execution and dilution risk that can hamper long‑term strategic initiatives.
Revenue Still Early‑stage And Partner/milestone DependentA material portion of current revenue is nonrecurring (grants, milestones, R&D reimbursements). Sustainable, high‑margin royalties and large commercial sales are not yet realized, leaving future revenue timing and scale dependent on partner commercialization and regulatory progress—structural execution risk.
Dyadic International News
DYAI FAQ
What was Dyadic International’s price range in the past 12 months?
Dyadic International lowest stock price was $0.65 and its highest was $1.35 in the past 12 months.
What is Dyadic International’s market cap?
Dyadic International’s market cap is $24.86M.
When is Dyadic International’s upcoming earnings report date?
Dyadic International’s upcoming earnings report date is Aug 12, 2026 which is in 61 days.
How were Dyadic International’s earnings last quarter?
Dyadic International released its earnings results on May 13, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.01.
Is Dyadic International overvalued?
According to Wall Street analysts Dyadic International’s price is currently Overvalued.
Does Dyadic International pay dividends?
Dyadic International does not currently pay dividends.
What is Dyadic International’s EPS estimate?
Dyadic International’s EPS estimate is -0.04.
How many shares outstanding does Dyadic International have?
Dyadic International has 36,438,700 shares outstanding.
What happened to Dyadic International’s price movement after its last earnings report?
Dyadic International reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Dyadic International?
Currently, no hedge funds are holding shares in DYAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dyadic International
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates. Dyadic also maintains several strategic alliances, including a research and development agreement with VTT Technical Research Centre of Finland, Ltd., a strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., and a collaboration with Syngene International Limited. Established in 1979, the company is headquartered in Jupiter, Florida.
DYAI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated clear operational and commercial progress: strong YoY revenue growth (182%), multiple product launches and shipments, expanded distribution and partner-funded biopharma validation (Gates and CEPI grants), and platform de-risking via Phase I and preclinical data. At the same time, the company remains early-stage with modest absolute revenues, rising cost of revenue (+~166%) and increased G&A (+10%), continued net losses, dependence on partner execution, and a cash runway that, while adequate into Q2 2027, may require future financing if product revenues do not scale. Overall, the tone is constructive and progress-focused but still highlights execution and scale risks typical of a company transitioning toward commercialization.View all DYAI earnings summariesDYAI Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
Collplant Holdings
―
Reviva Pharmaceuticals Holdings
―
―
Rani Therapeutics Holdings
―
Ownership Overview
16.31% Insiders
3.25% Mutual Funds
7.24% Other Institutional Investors
70.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---